Rheumatologists currently have multiple therapeutic options for treating RA patients including; 5 tumor necrosis factor inhibitors, 4 anti-cytokine biologics, anti-B cell monoclonal antibodies (rituximab), a T cell co-stimulation modulator (abatacept), or 3 small-molecule JAK inhibitors (tofacitinib, baricitinib, and upadacitinib), in addition to a growing number of biosimilars. Here, TNF is linked to rheumatoid arthritis.